Ozempic Weight Loss: Clinical Data & Individual Factors

Last reviewed: May 24, 2026

Last updated: May 24, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Clinical trials show Ozempic (semaglutide) produces an average weight loss of 4–15% of body weight over 68 weeks, with higher doses typically producing greater loss. However, individual responses span a wide range: some patients lose 5% while others achieve 20% or more. This variability reflects differences in metabolism, insulin sensitivity, baseline biology, and how your body responds to GLP-1 signaling.

Rather than focusing solely on average outcomes, understanding your personal biological context—including your genetic predispositions in peptide-response pathways and metabolic biomarkers—can help you and your provider make more informed treatment decisions. PlexusDx's precision-wellness approach uses genetic testing and compounded GLP-1 options to support a conversation tailored to your individual needs.

Clinical Trial Data on GLP-1 Weight Loss

In the STEP trials (2021–2022), Ozempic at 1.0 mg weekly produced a mean weight loss of 9.2% of body weight over 68 weeks in people with obesity. The 2.4 mg dose—the standard for weight loss (marketed as Wegovy)—showed greater loss, averaging around 15% of body weight. These figures represent statistically significant reductions compared to placebo, which showed roughly 2–3% weight loss.

Importantly, not all participants achieved the same results. The trials reported that approximately 35% of participants on semaglutide 2.4 mg lost 20% or more of their body weight, while some lost less than 10%. This spread illustrates that medication name and dose alone do not predict individual outcomes—your underlying biology matters significantly.

Factors Influencing Individual Weight Loss Response

Multiple biological, behavioral, and genetic factors affect how much weight someone loses on GLP-1 therapy. Insulin resistance, baseline metabolic rate, appetite-hormone sensitivity, diet adherence, physical activity, and even sleep quality all play roles. Additionally, genetic variations in GLP-1 receptor function, GIPR signaling, and fat-storage genes can influence how your body responds to the medication and how effectively appetite suppression works for you.

Factor Category	How It Affects Response
Baseline Insulin Sensitivity	Higher insulin resistance may correlate with greater initial weight loss, as GLP-1 improves insulin action and reduces compensatory eating.
Appetite-Hormone Genetics	Variants in GLP1R and GIPR genes may modulate medication efficacy; testing can reveal your predisposition in these pathways.
Behavioral Adherence	Consistent meal timing, protein intake, and physical activity enhance outcomes; medication alone is not sufficient for sustained loss.
Metabolic Rate & Body Composition	Individual resting metabolic rate and baseline fat distribution influence both starting point and achievable weight loss percentage.
Gastrointestinal Tolerance	Side effects such as nausea may reduce food intake further but can also reduce medication adherence if not managed with provider support.

Why Individual Variability Matters More Than Brand Names

The medication formulation—whether branded Ozempic, compounded semaglutide, Mounjaro, or a compounded tirzepatide—matters less for weight loss potential than your individual metabolic context. Semaglutide at equivalent doses produces similar GLP-1 receptor activation whether branded or compounded from a licensed 503A pharmacy. What differs is your body's baseline sensitivity to GLP-1 signaling, your insulin dynamics, and how well the medication's mechanism aligns with your specific physiology.

This is why PlexusDx offers both a Precision Peptide Genetic Test and multiple compounded GLP-1 options. Understanding your genetic predispositions in peptide-response pathways—such as GLP1R rs6923761 and GIPR rs1800437 variants—may help contextualize why you might expect a certain range of response, and that information can guide conversations about dosing strategy, medication choice, or the addition of complementary therapies.

Safety, Eligibility, and When GLP-1 Therapy Is Appropriate

GLP-1 medications are approved for weight loss in people with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with weight-related health conditions. However, they are not appropriate for everyone. Contraindications include personal or family history of medullary thyroid cancer, Multiple Endocrine Neoplasia syndrome type 2, and certain gastrointestinal conditions. Pregnancy, breastfeeding, and uncontrolled diabetes require careful provider evaluation. Common side effects include nausea, vomiting, constipation, and reduced appetite—most mild and manageable, but some people discontinue therapy due to tolerability.

Before starting any GLP-1 therapy—branded or compounded—a qualified healthcare provider should evaluate your medical history, current medications, metabolic labs, and specific goals. PlexusDx supports this conversation by offering genetic testing to reveal your peptide-pathway predispositions and access to compounded formulations through licensed 503A pharmacies, allowing your provider to personalize both the medication and dosing approach to your individual biology.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context by revealing your genetic predispositions in key peptide-signaling pathways—specifically GLP1R, GIPR, FTO, and MC4R variants. These genetic markers do not determine your exact weight loss outcome, but they can help illuminate your underlying metabolic and appetite-regulation biology. This information, interpreted with a qualified healthcare provider, supports a more informed discussion about whether GLP-1 therapy is a good fit and what dose or formulation might align best with your biology.

The genetic variants assessed by the Precision Peptide test (such as GLP1R rs6923761 and GIPR rs1800437) relate to how your body's GLP-1 and GIP receptors function at a baseline level. Individuals with certain variants may have naturally higher or lower receptor sensitivity, which could theoretically influence medication response. However, genetics alone do not predict exact medication response—lifestyle, concurrent health conditions, and treatment adherence remain critical determinants of outcomes.

Understanding your genetic predispositions can support a more personalized conversation with your provider about treatment strategy. Combined with PlexusDx's access to compounded semaglutide ($149/mo), compounded tirzepatide ($249/mo), and combination protocols, this information helps your provider match you to a formulation and dosing plan aligned with your individual biology rather than relying solely on average trial data.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.